

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Pulse Health Limited
ABN	69 104 113 760

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Phillipa Blakey
Date of last notice	1 April 2016

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	DIRECT
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. DIRECT Phillipa Blakey INDIRECT	1. 13,638 ORDINARY SHARES 2. 175,000 <u>UNLISTED</u> PERFORMANCE RIGHTS, TRANCHE 4, EXPIRY DATE 31/12/2017 AND PRICE HURDLE \$0.84 N/A
Date of change	31 December 2016

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

<p>No. of securities held prior to change Phillipa Blakey</p>	<p>DIRECT</p> <ol style="list-style-type: none"> 1. 13,638 ORDINARY SHARES 2. 525,000 UNLISTED PERFORMANCE RIGHTS, TRANCHE 3, EXPIRY DATE 31/12/2016 AND PRICE HURDLE \$0.72 3. 175,000 UNLISTED PERFORMANCE RIGHTS, TRANCHE 4, EXPIRY DATE 31/12/2017 AND PRICE HURDLE \$0.84 <p>INDIRECT N/A</p>
<p>Class</p>	<ol style="list-style-type: none"> 2. UNLISTED PERFORMANCE RIGHTS, TRANCHE 3, EXPIRY DATE 31/12/2016 AND PRICE HURDLE \$0.72
<p>Number acquired Phillipa Blakey</p>	<p>DIRECT N/A</p> <p>INDIRECT N/A</p>
<p>Number disposed</p>	<p>DIRECT</p> <ol style="list-style-type: none"> 2. (525,000) UNLISTED PERFORMANCE RIGHTS, TRANCHE 3, EXPIRY DATE 31/12/2016 AND PRICE HURDLE \$0.72 <p>INDIRECT N/A</p>
<p>Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation</p>	<p>N/A LAPSING OF PERFORMANCE RIGHTS, TRANCHE 3, EXPIRY DATE 31/12/2016 AND PRICE HURDLE \$0.72.</p>
<p>No. of securities held after change Phillipa Blakey</p>	<p>DIRECT</p> <ol style="list-style-type: none"> 1. 13,638 ORDINARY SHARES 2. 175,000 <u>UNLISTED</u> PERFORMANCE RIGHTS, TRANCHE 4, EXPIRY DATE 31/12/2017 AND PRICE HURDLE \$0.84 <p>INDIRECT N/A</p>
<p>Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>LAPSE OF UNLISTED PERFORMANCE RIGHTS TRANCHE 3, PER TERMS AND CONDITIONS DETAILS IN THE EGM NOTICE OF MEETING ON 26 MAY 2014</p>

+ See chapter 19 for defined terms.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	NO
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.